1] Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia [2] Deptartment of Pathology, University of Melbourne, Parkville, Victoria, Australia.
Immunol Cell Biol. 2013 Oct;91(9):556-67. doi: 10.1038/icb.2013.41. Epub 2013 Aug 20.
Signal transducer and activator of transcription 1 (Stat1) mediates anti-viral responses and cytokine-driven anti-proliferative, apoptotic and immunomodulatory activities. As de-regulated Stat1 function can affect tumour progression we sought to elucidate the effects of tumour cell-intrinsic Stat1 expression on immunosurveillance. Knockout of Stat1 enhanced the development of sarcomas induced by the chemical carcinogen 3-methylcholanthrene (MCA). Growth of transplanted MCA-induced Stat1⁻/⁻ sarcomas was suppressed in wild-type mice compared to growth in Stat1⁻/⁻ and immunocompromised recipients. Co-depletion of NK and CD8⁺ T cells from wild-type mice facilitated Stat1-deficient tumour growth whereas depletion of CD4⁺ T cells and CD8⁺ T cells did not. In vitro and in vivo analysis of the tumours implicated a role for NK cell-mediated, perforin-dependent killing of Stat1-deficient tumours. Interestingly, restoration of Stat1 expression in Stat1⁻/⁻ tumours resulted in diminished involvement of NK cells and increased contribution of CD8⁺ T cells in anti-tumour responses. Therefore, Stat1 expression within tumour cells modulated anti-tumour immune responses by altering the dominant immune effector cell involvement from NK cells to CD8⁺ T cells in the absence or presence of Stat1 respectively.
信号转导子和转录激活子 1(Stat1)介导抗病毒反应和细胞因子驱动的抗增殖、凋亡和免疫调节活性。由于失调的 Stat1 功能可能会影响肿瘤的进展,因此我们试图阐明肿瘤细胞内 Stat1 表达对免疫监视的影响。Stat1 基因敲除增强了化学致癌剂 3-甲基胆蒽(MCA)诱导的肉瘤的发展。与在 Stat1⁻/⁻和免疫缺陷受体中相比,在野生型小鼠中,移植的 MCA 诱导的 Stat1⁻/⁻肉瘤的生长受到抑制。从野生型小鼠中共同耗竭 NK 和 CD8⁺ T 细胞促进了 Stat1 缺陷肿瘤的生长,而耗竭 CD4⁺ T 细胞和 CD8⁺ T 细胞则没有。对肿瘤的体外和体内分析表明,NK 细胞介导的、穿孔素依赖性杀伤 Stat1 缺陷肿瘤起作用。有趣的是,在 Stat1⁻/⁻肿瘤中恢复 Stat1 表达导致 NK 细胞的参与减少,并且在存在或不存在 Stat1 的情况下,CD8⁺ T 细胞在抗肿瘤反应中的贡献增加。因此,肿瘤细胞内 Stat1 的表达通过改变免疫效应细胞的主要参与类型,从 NK 细胞到 CD8⁺ T 细胞,分别在缺乏或存在 Stat1 的情况下调节抗肿瘤免疫反应。